Skip to main content

Table 3 Serum PG, G-17 and status of HP in each group

From: Clinical applicability of a new scoring system for population-based screening and risk factors of gastric cancer in the Wannan region

Group (n)

PGI (ng/ml)

PGII (ng/ml)

PGR

G-17 (mmol/l)

Hp (+)

n (%)

Non atrophic gastritis group (655)

130.34 ± 68.33

13.95 ± 7.74

10.68 ± 5.39

5.53 (2.95, 10.56)

284 (43.36)

Atrophic gastritis group (52)

122.27 ± 52.77*

18.84 ± 11.13*

7.37 ± 2.78*

5.53 (4.24, 9.02)

26* (50.00)

Gastric ulcer group (109)

169.85 ± 84.51*

20.09 ± 11.50*

9.69 ± 4.85

5.96 (3.77, 11.25)*

71* (65.14)

Non-neoplastic polyp group (79)

132.37 ± 62.39

19.37 ± 11.58*

8.49 ± 5.62*

6.39 (4.53, 10.95)*

39 (49.37)

Precancerous lesion group (94)

109.70 ± 60.57*

18.08 ± 10.49*

6.95 ± 3.56*

6.65 (4.06, 13.02)*

58* (61.70)

Early cancer group (12)

98.61 ± 72.45*

17.26 ± 5.81*

6.13 ± 4.11*

5.89 (4.96, 13.24)*

7* (58.33)

Advanced cancer group (15)

66.30 ± 29.97*

19.70 ± 8.84*

4.54 ± 4.95*

10.6 (4.83, 16.26)*

10* (66.67)

P

 < 0.001

 < 0.001

 < 0.001

0.003

 < 0.001

  1. GC gastric cancer, Hp Helicobacter pylori, PGR pepsinogen ratio, G-17 gastrin-17
  2. Compared with non-atrophic gastritis group, *P < 0.05